U.S. Markets close in 5 hrs 36 mins

NovelStem International Corp. (NSTM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.28000.0000 (0.00%)
As of 11:28AM EST. Market open.

NovelStem International Corp.

2255 Glades Road
Suite 221A
Boca Raton, FL 33431
United States

IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Mitchell RubensteinCo-Founder & Director665.2kN/A1954
Mr. David CollinsInvestor Relations Firm, Catalyst IRN/AN/AN/A
Amounts are as of December 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NovelStem International Corp. focuses on developing and commercialization of diagnostic technology that can predict patients' resistance to chemotherapy allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. It has a collaboration agreement with NewStem Ltd. for stem-cell technology platform in cancer immunotherapy and COVID-19 resistance. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from advertising services to stem cell-based diagnostics for cancer chemotherapies. The company was founded in 1993 and is headquartered in Boca Raton, Florida.

Corporate Governance

NovelStem International Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.